Back to Search
Start Over
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
- Source :
-
JACC. Heart failure [JACC Heart Fail] 2020 Jan; Vol. 8 (1), pp. 70-80. Date of Electronic Publication: 2019 Aug 07. - Publication Year :
- 2020
-
Abstract
- Background: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival.<br />Objectives: This study sought to determine the relevance of sNEP as a biomarker in heart failure with preserved ejection fraction (HFpEF) and to compare circulating sNEP levels in patients with HFpEF with normal controls.<br />Methods: A case-control study was performed in 242 symptomatic patients with HFpEF previously enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) and Nitrates's Effect on Activity Tolerance in Heart Failure With Preserved Ejection (NEAT-HFpEF) clinical trials and 891 asymptomatic subjects without HF or diastolic dysfunction (confirmed by NT-proBNP levels <200 pg/ml and echocardiography) who were enrolled in the Prevalence of Asymptomatic Left Ventricular Dysfunction study. sNEP was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) in all subjects.<br />Results: Overall, sNEP levels were lower in HFpEF compared with controls (3.5 ng/ml; confidence interval [CI]: 2.5 to 4.8 vs. 8.5 ng/ml; CI: 7.2 to 10.0; p < 0.001). After adjusting for age, gender, body mass index (BMI), and smoking history, mean sNEP levels were also lower in HFpEF compared with controls (4.0 ng/ml [CI: 2.7 to 5.4] vs. 8.2 ng/ml [CI: 6.8 to 9.7]; p = 0.002). The cohorts were propensity matched based on age, BMI, diabetes, hypertension, smoking history, and renal function, and sNEP levels remained lower in HFpEF compared with controls (median 2.4 ng/ml [interquartile range: 0.6 to 27.7] vs. 4.9 ng/ml [interquartile range: 1.2 to 42.2]; p = 0.02).<br />Conclusions: Patients with HFpEF on average have significantly lower circulating sNEP levels compared with controls. These findings challenge our current understanding of the complex biology of circulating sNEP in HFpEF.<br /> (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Aged
Angiotensin Receptor Antagonists therapeutic use
Biomarkers blood
Biphenyl Compounds
Case-Control Studies
Drug Combinations
Echocardiography
Female
Heart Failure diagnosis
Heart Failure drug therapy
Heart Failure physiopathology
Heart Ventricles diagnostic imaging
Heart Ventricles physiopathology
Humans
Male
Middle Aged
Neprilysin antagonists & inhibitors
Valsartan
Ventricular Function, Left physiology
Aminobutyrates therapeutic use
Heart Failure blood
Neprilysin blood
Stroke Volume physiology
Tetrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2213-1787
- Volume :
- 8
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- JACC. Heart failure
- Publication Type :
- Academic Journal
- Accession number :
- 31392960
- Full Text :
- https://doi.org/10.1016/j.jchf.2019.07.005